SIL as Maintenance Therapy in Multiple Myeloma

Inclusion Criteria: * Pathologically confirmed Multiple Myeloma according World Health Organization (WHO) classification; * Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF). * Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted; * Patient is willing and able to adhere to the study visit schedule and other protocol requirements; * Documented response to ASCT (PR, VGPR, CR/stringent complete response \[sCR\]) according to IMWG criteria. Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy. * Pregnant or lactating women